Dkt. 0575/57005-B/JPW/AJM/APE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

icants: Robert J. Winchester, et al.

OCT 0 3 2001

· Box Sep

Serial No.:

09/500,746

Filed

TECH CENTER 1600/2900

For

February 9, 2000

USES OF INHIBITORS FOR THE ACTIVATION OF CXCR4

RECEPTOR BY SDF-1 IN TREATING RHEUMATOID

ARTHRITIS

1185 Avenue of the Americas New York, New York 10036 September 25, 2001

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

AMENDMENT IN RESPONSE TO

JUNE 25, 2001 COMMUNICATION REGARDING NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES AND PETITION FOR A TWO-MONTH EXTENSION OF TIME

This Amendment is submitted in response to the June 25, 2001 Communication Regarding Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. A copy of the Notice to Comply is attached hereto as Exhibit A. A response to the June 25, 2001 Notice was originally due July 25, 2001. Applicants hereby request a twomonth extension of time to September 25, 2001. The fee for a two-month extension of time is ONE HUNDRED FIFTY-FIVE DOLLARS (\$155.00) for a small entity. Applicants have previously established small entity status and check for this amount is enclosed herewith. Therefore, a reply to the June 25, 2001 Communication is now due September 25, 2001. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

10/02/2001 HMDDR1 00000019 033125 09500746 01 FC:216 40.00 CH 155.00 GP